Last updated: 2 July 2019 at 12:27am EST

Capital Partners, Llc Longi... Net Worth




The estimated Net Worth of Capital Partners, Llc Longi... is at least $16.4 Millón dollars as of 17 November 2014. Capital Longi owns over 487,130 units of Esperion Therapeutics stock worth over $49,044 and over the last 11 years Capital sold ESPR stock worth over $16,354,698.

Capital Longi ESPR stock SEC Form 4 insiders trading

Capital has made over 4 trades of the Esperion Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently Capital sold 487,130 units of ESPR stock worth $15,968,121 on 17 November 2014.

The largest trade Capital's ever made was selling 487,130 units of Esperion Therapeutics stock on 17 November 2014 worth over $15,968,121. On average, Capital trades about 179,169 units every 126 days since 2013. As of 17 November 2014 Capital still owns at least 28,186 units of Esperion Therapeutics stock.

You can see the complete history of Capital Longi stock trades at the bottom of the page.



Insiders trading at Esperion Therapeutics

Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio... y Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.



What does Esperion Therapeutics do?

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.



What does Esperion Therapeutics's logo look like?

Esperion Therapeutics Inc. logo

Complete history of Capital Longi stock trades at Esperion Therapeutics

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
17 Nov 2014 Capital Partners, Llc Longi...
Venta 487,130 $32.78 $15,968,121
17 Nov 2014
28,186
9 Oct 2014 Capital Partners, Llc Longi...
Venta 943 $30.00 $28,290
9 Oct 2014
37,757
7 Oct 2014 Capital Partners, Llc Longi...
Venta 11,927 $30.04 $358,287
7 Oct 2014
37,776
1 Jul 2013 Capital Partners, Llc Longi...
Comprar 216,676 $14.00 $3,033,464
1 Jul 2013
38,011


Esperion Therapeutics executives and stock owners

Esperion Therapeutics executives and other stock owners filed with the SEC include: